Signals Analytics is offering a COVID-19 Playbook at no cost to researchers looking to monitor vaccines that are in development for COVID-19 and other strains of coronavirus; monitor trending drugs that are being tested for COVID-19; and assess which drugs are being repurposed to help treat infected people.
The COVID-19 Playbook is a front-end user interface of the Signals Analytics platform powered by advanced analytics, patented Natural Language Processing techniques, and taxonomies developed by domain experts with years of academic and pharmaceutical industry experience. It connects data from a wide range of sources, including clinical trials, research papers, business events, announcements, media coverage, drug developments, and more. Context is extracted from the various data types and visualizations and actionable insights are generated, the company says.
The COVID-19 Playbook is aimed at heads of research, development, and innovation as well as leaders responsible for growth, business development, and mergers and acquisitions who are looking for ways to speed up the vaccine and drug discovery process. The resource’s aggregated dashboards address many important business questions, such as: what are the leading and emerging targets being analyzed for COVID-19, which are the leading and emerging drugs and vaccines that are being researched and tested, which drugs are being repurposed to treat COVID-19, and which entities are leading and emerging for COVID-19 testing and treatment.
Further, on March 30, Signals Analytics will sponsor a FiercePharma webinar on “The Race to Develop a Vaccine for COVID-19,” during which the pharma company will feature some early findings from its own analysis on the COVID-19 Playbook. The webinar is part of the “Coronavirus Virtual Series,” a two-day, free event.
Edited by Michael Causey
